CVM Logo

CEL-SCI Corp (CVM) Stock Forecast & Price Prediction

Live CVM Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Biotechnology

$0.38

-0.01 (-2.85%)

12 Month Price Forecast For CVM

$0.38
Current Price
$28.43M
Market Cap
2 Ratings
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to CVM Price Forecasts

+2,539.2%
To High Target of $10.00
+1,747.5%
To Median Target of $7.00
+1,536.3%
To Low Target of $6.20

CVM Price Momentum

-2.6%
1 Week Change
+2.7%
1 Month Change
-86.7%
1 Year Change
-5.0%
Year-to-Date Change
-87.6%
From 52W High of $3.05
+5.2%
From 52W Low of $0.36

๐Ÿค” Considering CEL-SCI (CVM)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 9:58 AM UTC

CVM Analyst Ratings & Price Targets

Based on our analysis of 3 Wall Street analysts, CVM has a consensus that is bullish. The median price target is $7.00, with forecasts ranging from $6.20 to $10.00. Currently, there are 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With CVM currently trading at $0.38, the median price forecast suggests a 1,747.5% upside. The most optimistic forecast comes from Tony Butler at EF Hutton, projecting a 2,539.2% upside, while at provides the most conservative target, suggesting a 1,536.3% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CVM Analyst Consensus

2
Buy
0
Hold
0
Sell

CVM Price Target Range

Low
$6.20
Average
$7.00
High
$10.00
Current: $0.38

Latest CVM Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CVM.

Date Firm Analyst Rating Change Price Target
Jul 12, 2023 EF Hutton Tony Butler Buy Reiterates $10.00
Mar 9, 2023 EF Hutton Tony Butler Buy Reiterates $10.00
Feb 17, 2023 EF Hutton Tony Butler Buy Assumes $10.00
Dec 29, 2022 EF Hutton Tim Moore Buy Maintains $16.00
Aug 25, 2022 EF Hutton Buy Initiates $0.00
Apr 7, 2022 EF Hutton Buy Initiates $0.00
Jan 13, 2020 HC Wainwright & Co. Buy Initiates $0.00
Jan 13, 2020 H.C. Wainwright Buy Initiates $0.00
Feb 20, 2013 Taglich Brothers Speculative Buy Initiates $0.00
Feb 13, 2013 Chardan Capital Buy Initiates $0.00
Jan 14, 2013 Laidlaw & Co. Buy Initiates $0.00

Stocks Similar to CEL-SCI Corp

The following stocks are similar to CEL-SCI based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

CEL-SCI Corp (CVM) Financial Data

CEL-SCI Corp has a market capitalization of $28.43M with a P/E ratio of -0.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -250.2%.

Valuation Metrics

Market Cap $28.43M
Enterprise Value $37.21M
P/E Ratio -0.7x
PEG Ratio -0.9x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +1.8%
Current Ratio 0.6x
Debt/Equity 143.2x
ROE -250.2%
ROA -61.4%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

CEL-SCI Corp logo

CEL-SCI Corp (CVM) Company Overview

About CEL-SCI Corp

What They Do

Develops immune therapies for cancer treatment.

Business Model

The company focuses on the research and development of immune system therapies, primarily generating revenue through the advancement of its clinical-stage products, particularly the Multikine immunotherapy. CEL-SCI is also developing additional products using its proprietary LEAPS technology, which targets various diseases, thereby expanding its potential market opportunities.

Additional Information

CEL-SCI Corporation has been operational since 1983 and is based in Vienna, Virginia. Its lead product has completed Phase 3 clinical trials, indicating a strong commitment to advancing cancer treatment options. The company is also exploring treatments for autoimmune conditions and has several LEAPS-based candidates in the preclinical stage.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

0

CEO

Mr. Geert R. Kersten Esq.

Country

United States

IPO Year

1991

CEL-SCI Corp (CVM) Latest News & Analysis

CVM stock latest news image
Quick Summary

CEL-SCI reported fiscal 2024 results and plans to begin a confirmatory study for Multikine, which may establish a new standard of care for head and neck cancer.

Why It Matters

CEL-SCI's confirmatory study for Multikine could establish a new treatment standard for head and neck cancer, potentially boosting market value and attracting investor interest.

Source: Business Wire
Market Sentiment: Neutral
CVM stock latest news image
Quick Summary

CEL-SCI has successfully closed a $5 million offering, as announced in Vienna, Virginia.

Why It Matters

CEL-SCI's $5 million offering indicates potential liquidity for growth, impacting stock valuation and investor confidence in the company's future projects.

Source: Business Wire
Market Sentiment: Neutral
CVM stock latest news image
Quick Summary

CEL-SCI Corporation has announced a proposed public offering of common stock.

Why It Matters

CEL-SCI's proposed public offering can dilute existing shares and impact stock price, signaling capital needs or growth strategies that may affect investor sentiment and valuation.

Source: Business Wire
Market Sentiment: Neutral
CVM stock latest news image
Quick Summary

CEL-SCI has announced a public offering priced at $5 million.

Why It Matters

CEL-SCI's $5 million public offering may dilute existing shares, impacting stock value and investor sentiment. It also signals the company's need for capital, which could affect future growth.

Source: Business Wire
Market Sentiment: Neutral
CVM stock latest news image
Quick Summary

CEL-SCI emphasizes the biological rationale for using Multikine in its Confirmatory Registration Study for head and neck cancer.

Why It Matters

Positive developments regarding Multikine's biological rationale may enhance its approval prospects, impacting CEL-SCI's stock price and investor sentiment in the biotech sector.

Source: Business Wire
Market Sentiment: Neutral
CVM stock latest news image
Quick Summary

CEL-SCI and the U.S. FDA have agreed to use the PD-L1 biomarker for selecting head and neck cancer patients in a marketing registration study set to begin in Q1 2025.

Why It Matters

FDA agreement on the PD-L1 biomarker for CEL-SCI's Multikine could enhance its market potential in head and neck cancer, impacting future revenue and stock performance.

Source: Business Wire
Market Sentiment: Neutral

Frequently Asked Questions About CVM Stock

What is CEL-SCI Corp's (CVM) stock forecast for 2025?

Based on our analysis of 3 Wall Street analysts, CEL-SCI Corp (CVM) has a median price target of $7.00. The highest price target is $10.00 and the lowest is $6.20.

Is CVM stock a good investment in 2025?

According to current analyst ratings, CVM has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.38. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CVM stock?

Wall Street analysts predict CVM stock could reach $7.00 in the next 12 months. This represents a 1,747.5% increase from the current price of $0.38. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is CEL-SCI Corp's business model?

The company focuses on the research and development of immune system therapies, primarily generating revenue through the advancement of its clinical-stage products, particularly the Multikine immunotherapy. CEL-SCI is also developing additional products using its proprietary LEAPS technology, which targets various diseases, thereby expanding its potential market opportunities.

What is the highest forecasted price for CVM CEL-SCI Corp?

The highest price target for CVM is $10.00 from Tony Butler at EF Hutton, which represents a 2,539.2% increase from the current price of $0.38.

What is the lowest forecasted price for CVM CEL-SCI Corp?

The lowest price target for CVM is $6.20 from at , which represents a 1,536.3% increase from the current price of $0.38.

What is the overall CVM consensus from analysts for CEL-SCI Corp?

The overall analyst consensus for CVM is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.

How accurate are CVM stock price projections?

Stock price projections, including those for CEL-SCI Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.